Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1393-1399

  Rehemtulla, Alnawaz ^a,b   Hamstra, Daniel A ^a   Kievit, Els ^a   Davis, Mary A ^a   Ng, Emily Y ^a   Dornfeld, Kenneth ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

5 Fluorouracil; Cytosine deaminase; Enzyme prodrug therapy; Gene therapy; Protein secretion

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; PRODRUG; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG RESPONSE; ENZYME INHIBITION; ENZYME THERAPY; EXTRACELLULAR SPACE; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT;

ANIMALS; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; EXTRACELLULAR FLUID; FEMALE; FLUOROURACIL; GENE THERAPY; MICE; MICE, NUDE; PLASMIDS; PRODRUGS; RATS; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3242673522     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Huber BE, Austin EA, Richards CA and Davis ST: Metabolism of 5-fluorocytosine to 5-flouorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994.
2. Crystal RG, Hirschowitz E, Lieberman M et al: Phase I study of direct administratin of a replication deficient advenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Human Gene Therapy 8: 985-1001, 1997.
3. Wygoda MR, Wilson M, Davis MA, Trosko JE, Rehemtulla A and Lawrence TS: Protection of HSV-TK tranduced cells from ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan Effect. Cancer Res 57: 1699-1703, 1997.
4. Lawrence TS, Rehemtulla R, Ng EY, Wilson M, Trosko JE and Stetson PL: Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 58: 2588-2593, 1998.
5. Byfield JE, Calabro-Jones P, Klisak I and Kulhanian F: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays. Int J Rad Oncol Biol Phys 8: 1923-1933, 1982.
6. Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
7. Ny T, Elgh F and Lund B: The structure of the human tissue-type plasminogen activator gene: Correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 81: 5355-5359, 1984.
8. Pennica D et al: Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301(5897): 214-21, 1983.
9. Lawrence TS, Davis MA, Maybaum J et al: The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res 52: 3698-3704, 1992.
10. Maley F, Pedersen-Lane J and Changchien L-M: Complete restoration of activity to inactive mutants of Escherichia coli thymidylate synthase: evidence the E. coli thymidylate synthase is a half-the-sites activity enzyme. Biochem 34: 1469-1479, 1995.
11. Trinh QT, Austin EA, Murray DM, Knick VC and Huber BE: Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55: 4808-4812, 1995.
12. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S and Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619-4626, 1993.
13. Hamstra DA, Rice DJ, Pu A, Oyedijo D, Ross B and Rehemtulla A: Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Rad Res 152: 499-507, 1999.
14. Kievit E et al: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenographs. Cancer Res 59: 1417-1421, 1999.
15. Uckert W et al: Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Human Gene Therapy 9: 855-865, 1998.
16. Cao X et al: Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor bearing mice. Gene Therapy 5: 1130-1136, 1998.
17. Koyama F et al: Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherchia coli cytosine deaminase gene and Escherichia coli uracil phophoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Therapy 7: 1015-1022, 2000.
18. Erbs P et al: In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 60: 3813-3822, 2000.
19. Kim JH et al: Selective radiosensitization of 9L Glioma in the brain transduced with double suicide fusion gene. Cancer J Sci American 4: 364-369, 1998.
20. Stegman LD et al: Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 96: 9821-9826, 1999.
21. Hamstra DA, Rice DJ, Fahmy S, Ross BD and Rehemtulla A: Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Human Gene Therapy 10: 1993-2003, 1999.
22. Ireton GC, McDermott G, Black ME and Stoddard BL: The structure of Escherichia coli cytosine deaminase. J Mol Biol 315: 687-97, 2002.
23. Weyel D, Sedlacek HH, Muller R and Brusselbach S: Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme produrg therapy. Gene Therapy 7: 224-231, 2000.
24. Heine D, Muller R and Brusselbach S: Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme produrg therapy. Gene Therapy 8: 1005-1010, 2001.
25. Marais R, Spooner R, Stribbling S, Light Y, Martin J and Springer C: A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnology 15: 1373-1377, 1997.
26. Friedlos F et al: Three new produrgs for suicide gene therapy using carboxypeptidase G2 eleict bystander efficacy in two xenograft models. Cancer Res 62: 1724-9, 2002.
27. Hamstra DA, Page M, Maybaum J and Rehemtulla A: Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res 60: 657-665, 2000.